<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age>66</patient-age><report-id>PHHO2012BR006600</report-id><gender>unknown</gender><reactions><reaction>Cardiac-respiratory arrest</reaction><reaction>Unstable angina grade 2</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>AMN107</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>ACETYLSALICYLIC ACID</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>ENALAPRIL</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>HYDROCHLOROTHIAZIDE</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>AMLODIPINE</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>FUROSEMIDE</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>NPH INSULIN</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Chronic myeloid leukaemia</indication><indication>Diabetes mellitus</indication><indication>Hypertension</indication></indications><outcomes><outcome>Death</outcome><outcome>Required Inpatient Hospitalization</outcome></outcomes><country>Brazil</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4149696_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125152634</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>2</safetyreportversion>
		<safetyreportid>PHHO2012BR006600</safetyreportid>
		<primarysourcecountry>BR</primarysourcecountry>
		<occurcountry>BR</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2013-01-25</transmissiondate>
		<reporttype>2</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>1</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-04-27</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2013-01-23</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHO2012BR006600</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reportergivename>Aline</reportergivename>
			<reporterfamilyname>Marcondes</reporterfamilyname>
			<reporterstreet>Rua Santa Marcelina, 91</reporterstreet>
			<reportercountry>BR</reportercountry>
			<qualification code="1">Physician</qualification>
			<sponsorstudynumb>CAMN107A2404</sponsorstudynumb>
			<observestudytype>1</observestudytype>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>JAS</patientinitial>
			<patientinvestigationnumb>14</patientinvestigationnumb>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19451001</patientbirthdate>
			<patientweight>90</patientweight>
			<patientheight>171</patientheight>
			<patientsex code="1">Male</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Hypertension</patientepisodename>
				<patientmedicalstartdateformat>610</patientmedicalstartdateformat>
				<patientmedicalstartdate>200411</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Diabetes mellitus</patientepisodename>
				<patientmedicalstartdateformat>610</patientmedicalstartdateformat>
				<patientmedicalstartdate>200810</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
			</medicalhistoryepisode>
			<patientdeath>
				<patientdeathdateformat>102</patientdeathdateformat>
				<patientdeathdate>20120716</patientdeathdate>
				<patientautopsyyesno>3</patientautopsyyesno>
				<patientdeathcause>
					<patientdeathreportmeddraversion>15.1</patientdeathreportmeddraversion>
					<patientdeathreport>Cardio-respiratory arrest</patientdeathreport>
				</patientdeathcause>
			</patientdeath>
			<reaction>
				<primarysourcereaction>Cardiac-respiratory arrest</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Cardio-respiratory arrest</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Cardio-respiratory arrest</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120427</reactionstartdate>
				<reactionfirsttime>5</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>2</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome code="5">fatal</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Unstable angina grade 2</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Unstable angina</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Angina unstable</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20120427</reactionstartdate>
				<reactionfirsttime>5</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>2</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120427</testdate>
				<testname>Electrocardiogram</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20120427</testdate>
				<testname>Troponin T</testname>
				<moreinformation>1</moreinformation>
			</test>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>AMN107</medicinalproduct>
				<obtaindrugcountry>BR</obtaindrugcountry>
				<drugauthorizationnumb>22-068</drugauthorizationnumb>
				<drugauthorizationcountry>BR</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>400</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>400 mg, daily</drugdosagetext>
				<drugdosageform normalized="capsule">Capsule</drugdosageform>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Chronic myeloid leukaemia</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-04-23</drugstartdate>
				<drugstartperiod>5</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod>2</druglastperiod>
				<druglastperiodunit>804</druglastperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-04-26</drugenddate>
				<drugtreatmentduration>4</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>AMN107</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Angina unstable</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Angina unstable</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Cardio-respiratory arrest</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Cardio-respiratory arrest</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>ACETYLSALICYLIC ACID</medicinalproduct>
				<obtaindrugcountry>BR</obtaindrugcountry>
				<drugauthorizationcountry>BR</drugauthorizationcountry>
				<drugstructuredosagenumb>100</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>100 mg, QD</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Diabetes mellitus</drugindication>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>2008-10-01</drugstartdate>
				<actiondrug code="4">Dose not changed</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ACETYLSALICYLIC ACID</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>ENALAPRIL</medicinalproduct>
				<obtaindrugcountry>BR</obtaindrugcountry>
				<drugauthorizationcountry>BR</drugauthorizationcountry>
				<drugstructuredosagenumb>100</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>100 mg, BID</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hypertension</drugindication>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>2004-11-01</drugstartdate>
				<actiondrug code="4">Dose not changed</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>ENALAPRIL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>HYDROCHLOROTHIAZIDE</medicinalproduct>
				<obtaindrugcountry>BR</obtaindrugcountry>
				<drugauthorizationcountry>BR</drugauthorizationcountry>
				<drugstructuredosagenumb>25</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>25 mg, QD</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hypertension</drugindication>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>2004-11-01</drugstartdate>
				<actiondrug code="4">Dose not changed</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>HYDROCHLOROTHIAZIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>AMLODIPINE</medicinalproduct>
				<obtaindrugcountry>BR</obtaindrugcountry>
				<drugauthorizationcountry>BR</drugauthorizationcountry>
				<drugstructuredosagenumb>5</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>5 mg, BID</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hypertension</drugindication>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>2004-11-01</drugstartdate>
				<actiondrug code="4">Dose not changed</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>AMLODIPINE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>FUROSEMIDE</medicinalproduct>
				<obtaindrugcountry>BR</obtaindrugcountry>
				<drugauthorizationcountry>BR</drugauthorizationcountry>
				<drugstructuredosagenumb>40</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>40 mg, QD</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Hypertension</drugindication>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>2004-11-01</drugstartdate>
				<actiondrug code="4">Dose not changed</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>FUROSEMIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>NPH INSULIN</medicinalproduct>
				<obtaindrugcountry>BR</obtaindrugcountry>
				<drugauthorizationcountry>BR</drugauthorizationcountry>
				<drugstructuredosagenumb>26</drugstructuredosagenumb>
				<drugstructuredosageunit code="032"/>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>26 U, QD</drugdosagetext>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Diabetes mellitus</drugindication>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>2008-10-01</drugstartdate>
				<actiondrug code="4">Dose not changed</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>INSULIN INJECTION, ISOPHANE</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHO2012BR006600, is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>report received on 27 Apr 2012, from clinical study CAMN107A2404. This 66-year old subject (subject number 14, center number 1073) was enrolled in CAMN107A2404: a randomised phase III open label study of <Semaphore x="699336" class="Medicine" value="imatinib" score="0.74" ID="252378">imatinib </Semaphore>dose optimization <Semaphore x="1803212" class="Procedure" value="Comparison of Screening Methods" score="1.00" ID="C62743">compared </Semaphore>with <Semaphore x="928154" class="Medicine" value="nilotinib" score="0.49" ID="278855">nilotinib </Semaphore>in subjects with <Semaphore x="1779493" class="Disease or Finding" value="Chronic Leukemia" score="1.00" ID="C3483">chronic <Semaphore x="3120003" class="MedDRA LLT" value="Myeloid leukaemia" score="1.00" ID="10028549">myelogenous leukemia </Semaphore></Semaphore>and suboptimal <Semaphore x="1854566" class="Disease or Finding" value="Disease Response" score="1.00" ID="C50995">response </Semaphore>to standard dose <Semaphore x="699336" class="Medicine" value="imatinib" score="0.74" ID="252378">imatinib</Semaphore>.The subject's medical history includes <Semaphore x="2038093" class="Disease or Finding" value="Hypertension" score="1.00" ID="C3117">hypertension </Semaphore>and <Semaphore x="1845561" class="Disease or Finding" value="Diabetes Mellitus" score="1.00" ID="C2985">diabetes mellitus</Semaphore>. Co medications include acetyl <Semaphore x="1162912" class="Medicine" value="Salicylic Acid" score="0.49" ID="297149">salicylic <Semaphore x="2147465" class="Procedure" value="Lysergide Measurement" score="1.00" ID="C75354">acid</Semaphore></Semaphore>, <Semaphore x="528227" class="Medicine" value="Enalapril" score="0.49" ID="266050">enalapril</Semaphore>, <Semaphore x="675434" class="Medicine" value="Hydrochlorothiazide" score="0.74" ID="270905">hydrochlorothiazide</Semaphore>, <Semaphore x="103656" class="Medicine" value="Amlodipine" score="0.74" ID="239933">amlodipine</Semaphore>, <Semaphore x="608230" class="Medicine" value="Furosemide" score="0.49" ID="269027">furosemide </Semaphore>and NPH <Semaphore x="733661" class="Medicine" value="Insulin" score="0.87" ID="275827">insulin</Semaphore>. The subject started study medication AMN107 on 23 Apr 2012 at a dose of 400 mg daily. On 25 Apr 2012 (3 days after study medication was started), the subject presented with symptoms including <Semaphore x="1926717" class="Disease or Finding" value="Fatigue" score="1.00" ID="C3036">fatigue</Semaphore>, <Semaphore x="2855022" class="MedDRA LLT" value="Chest pain" score="1.00" ID="10008479"><Semaphore x="1761238" class="Disease or Finding" value="Chest Pain" score="1.00" ID="C38665">chest <Semaphore x="2441971" class="Disease or Finding" value="Radiating Pain" score="1.00" ID="C101178">pain </Semaphore></Semaphore>
     </Semaphore>
    <Semaphore x="2441971" class="Disease or Finding" value="Radiating Pain" score="1.00" ID="C101178">radiating </Semaphore>to <Semaphore x="2101093" class="AnatomicStructure" value="Left Arm" score="1.00" ID="C105633">left superior arm</Semaphore>, <Semaphore x="2895923" class="MedDRA LLT" value="Decreased appetite" score="1.00" ID="10061428">inappetence </Semaphore>and <Semaphore x="1870759" class="Disease or Finding" value="Dyspnea" score="1.00" ID="C2998">dyspnea </Semaphore>on 27 Apr 2012. On 27 Apr 2012, the subject was <Semaphore x="1846062" class="Procedure" value="Diagnosis" score="1.00" ID="C15220">diagnosed </Semaphore>with <Semaphore x="2665843" class="Disease or Finding" value="Unstable Angina" score="1.00" ID="C66911">unstable angina </Semaphore><Semaphore x="2027225" class="Procedure" value="Histopathologic Examination" score="1.00" ID="C18190">grade </Semaphore>2 and was admitted to the hospital due to the event. <Semaphore x="1877067" class="Procedure" value="Electrocardiography" score="1.00" ID="C38053">Electrocardiogram </Semaphore>on 27 Apr 2012 was abnormal and <Semaphore x="2644449" class="Procedure" value="Troponin T Measurement" score="1.00" ID="C74750">troponin T </Semaphore>was measured as 0.060. The subject was <Semaphore x="1846062" class="Procedure" value="Diagnosis" score="1.00" ID="C15220">diagnosed </Semaphore>with <Semaphore x="1870759" class="Disease or Finding" value="Dyspnea" score="1.00" ID="C2998">dyspnea</Semaphore>, <Semaphore x="1926717" class="Disease or Finding" value="Fatigue" score="1.00" ID="C3036">fatigue </Semaphore>on 27 Apr 2012. The <Semaphore x="2394286" class="Procedure" value="Pharmacotherapy" score="1.00" ID="C15986">treatment with study medication </Semaphore>was discontinued due to the event on an unknown date. The subject was referred to emergency where <Semaphore x="2724216" class="MedDRA LLT" value="Adverse event" score="1.00" ID="10060933">adverse event </Semaphore>was under <Semaphore x="3049513" class="MedDRA LLT" value="Investigation" score="1.00" ID="10062026">investigation</Semaphore>. The subject was treated with <Semaphore x="315365" class="Medicine" value="cefepime" score="0.49" ID="241833">cefepime</Semaphore>, <Semaphore x="493397" class="Medicine" value="Dipyrone" score="0.49" ID="258262">Dipyrone</Semaphore>, Plasil, acetylsalicylic <Semaphore x="2147465" class="Procedure" value="Lysergide Measurement" score="1.00" ID="C75354">acid</Semaphore>, <Semaphore x="2692070" class="Procedure" value="Vitamin B12 Measurement" score="1.00" ID="C64817">vitamin B12</Semaphore>, <Semaphore x="1184873" class="Medicine" value="Simvastatin" score="0.49" ID="260057">simvastatin</Semaphore>, <Semaphore x="749994" class="Medicine" value="Isosorbide" score="0.49" ID="276549">isosorbide</Semaphore>, <Semaphore x="383365" class="Medicine" value="clopidogrel" score="0.49" ID="253930">clopidogrel</Semaphore>, <Semaphore x="733661" class="Medicine" value="Insulin" score="0.87" ID="275827">insulin </Semaphore>NPH, <Semaphore x="733661" class="Medicine" value="Insulin" score="0.87" ID="275827">insulin </Semaphore>regular, <Semaphore x="658468" class="Medicine" value="Heparin" score="0.49" ID="269926">heparin</Semaphore>, <Semaphore x="39079" class="Medicine" value="Acetylcysteine" score="0.49" ID="240120">acetylcysteine</Semaphore>, <Semaphore x="2737985" class="MedDRA LLT" value="Analgesic drug level" score="1.00" ID="10060090">paracetamol</Semaphore>, <Semaphore x="652004" class="Medicine" value="Haldol" score="0.49" ID="239548">Haldol</Semaphore>, <Semaphore x="103656" class="Medicine" value="Amlodipine" score="0.74" ID="239933">amlodipine</Semaphore>, <Semaphore x="675434" class="Medicine" value="Hydrochlorothiazide" score="0.74" ID="270905">hydrochlorothiazide</Semaphore>, <Semaphore x="857859" class="Medicine" value="metFORMIN" score="0.49" ID="279450">metformin </Semaphore>and <Semaphore x="673983" class="Medicine" value="Hydrea" score="0.49" ID="239551">Hydrea</Semaphore>. At the time of the report, the subject was <Semaphore x="1552503" class="Disease or Finding" value="Asymptomatic" score="1.00" ID="C3833">asymptomatic</Semaphore>, hemodynamically stable. The subject was presented at the hospital on 16 Jul 2012 with <Semaphore x="1722367" class="Disease or Finding" value="Cardiac Arrest" score="1.00" ID="C50479">cardiac <Semaphore x="2463617" class="Disease or Finding" value="Respiratory Arrest" score="1.00" ID="C101772">respiratory arrest</Semaphore></Semaphore>. The subject was treated with Atropina, Dopamina, Dipirona and <Semaphore x="1119916" class="Medicine" value="Ranitidine" score="0.49" ID="296868">ranitidine</Semaphore>. The subject underwent <Semaphore x="1724126" class="Procedure" value="Cardiac Resuscitation" score="1.00" ID="C102971">cardiac <Semaphore x="3230351" class="MedDRA LLT" value="Resuscitation" score="1.00" ID="10038749">resuscitation </Semaphore></Semaphore>without success and died on the same day at 09.25 am. No autopsy was performed. The investigator indicated that the events were not due to progression of underlying illness or lack of efficacy. The <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of <Semaphore x="2665843" class="Disease or Finding" value="Unstable Angina" score="1.00" ID="C66911">unstable angina </Semaphore>was unknown. The event of <Semaphore x="1722367" class="Disease or Finding" value="Cardiac Arrest" score="1.00" ID="C50479">cardiac <Semaphore x="2463617" class="Disease or Finding" value="Respiratory Arrest" score="1.00" ID="C101772">respiratory arrest </Semaphore></Semaphore>was reported as serious (fatal, <Semaphore x="3012166" class="MedDRA LLT" value="Hospitalisation" score="1.00" ID="10054112">hospitalization</Semaphore>). According to the investigator, the event <Semaphore x="2665843" class="Disease or Finding" value="Unstable Angina" score="1.00" ID="C66911">unstable angina </Semaphore>was reported as serious (<Semaphore x="3012166" class="MedDRA LLT" value="Hospitalisation" score="1.00" ID="10054112">hospitalization</Semaphore>).The investigator reported that the events were related to <Semaphore x="2394286" class="Procedure" value="Pharmacotherapy" score="1.00" ID="C15986">treatment with study medication</Semaphore>.Follow up received on 11 May 2012: clinical course along with <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>was updated.Follow up combined report (3) received on 17 May 2012: The resolution date and <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of events <Semaphore x="2918626" class="MedDRA LLT" value="Dyspnoea" score="1.00" ID="10013968">dyspnoea</Semaphore>, <Semaphore x="2923295" class="MedDRA LLT" value="Electrocardiogram abnormal" score="1.00" ID="10014363">abnormal <Semaphore x="1877067" class="Procedure" value="Electrocardiography" score="1.00" ID="C38053">electrocardiogram </Semaphore></Semaphore>and <Semaphore x="1926717" class="Disease or Finding" value="Fatigue" score="1.00" ID="C3036">fatigue </Semaphore>was updated.Follow up received on 22 May 2012: Updated study medication (subject received AMN107), re confirmed of causality (suspected) and <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>medications.Follow up <Semaphore x="1862781" class="Race" value="Dominican" score="1.00" ID="C67117">DR </Semaphore>report received on 29 May 2012: The investigator reported that, the events <Semaphore x="2895923" class="MedDRA LLT" value="Decreased appetite" score="1.00" ID="10061428">inappetence </Semaphore>and <Semaphore x="2855022" class="MedDRA LLT" value="Chest pain" score="1.00" ID="10008479"><Semaphore x="1761238" class="Disease or Finding" value="Chest Pain" score="1.00" ID="C38665">chest <Semaphore x="2441971" class="Disease or Finding" value="Radiating Pain" score="1.00" ID="C101178">pain </Semaphore></Semaphore>
     </Semaphore>
    <Semaphore x="2441971" class="Disease or Finding" value="Radiating Pain" score="1.00" ID="C101178">radiating </Semaphore>to <Semaphore x="2101093" class="AnatomicStructure" value="Left Arm" score="1.00" ID="C105633">left superior arm </Semaphore>were not serious <Semaphore x="2811880" class="MedDRA LLT" value="Blood lead" score="1.00" ID="10005639">lead </Semaphore>events. The events <Semaphore x="2918626" class="MedDRA LLT" value="Dyspnoea" score="1.00" ID="10013968">dyspnoea</Semaphore>, <Semaphore x="2923295" class="MedDRA LLT" value="Electrocardiogram abnormal" score="1.00" ID="10014363">abnormal <Semaphore x="1877067" class="Procedure" value="Electrocardiography" score="1.00" ID="C38053">electrocardiogram </Semaphore></Semaphore>and <Semaphore x="1926717" class="Disease or Finding" value="Fatigue" score="1.00" ID="C3036">fatigue </Semaphore>were only serious events.Follow up (3) received on 27 Jul 2012: Update main <Semaphore x="1846062" class="Procedure" value="Diagnosis" score="1.00" ID="C15220">diagnosis </Semaphore>(<Semaphore x="1722367" class="Disease or Finding" value="Cardiac Arrest" score="1.00" ID="C50479"><Semaphore x="2840299" class="MedDRA LLT" value="Cardiac arrest" score="1.00" ID="10007515"><Semaphore x="1722367" class="Disease or Finding" value="Cardiac Arrest" score="1.00" ID="C50479">cardiac <Semaphore x="2463617" class="Disease or Finding" value="Respiratory Arrest" score="1.00" ID="C101772">respiratory arrest</Semaphore></Semaphore>
      </Semaphore>
     <Semaphore x="1537270" class="Disease or Finding" value="Apnea" score="1.00" ID="C26698">), </Semaphore></Semaphore><Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>details, event <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>and causality.Follow up <Semaphore x="1862781" class="Race" value="Dominican" score="1.00" ID="C67117">DR </Semaphore>report received on 23 Jan 2013: Updated <Semaphore x="1846062" class="Procedure" value="Diagnosis" score="1.00" ID="C15220">new diagnosis </Semaphore>(<Semaphore x="2665843" class="Disease or Finding" value="Unstable Angina" score="1.00" ID="C66911">unstable angina </Semaphore><Semaphore x="2027225" class="Procedure" value="Histopathologic Examination" score="1.00" ID="C18190">grade </Semaphore>2) with onset, seriousness, causality and <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome</Semaphore>.</narrativeincludeclinical>
				<sendercomment>Listed events. The investigator reported that the events were related to treatment with study medication.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>